Last mentioned: Mar 20, 2026
Bilal Cassim’s public testimony regarding the efficacy of medicinal cannabis for PTSD and sleep disorders highlights a growing trend of patient-led advocacy in Australia. This case underscores the shifting clinical landscape as researchers and regulators grapple with the integration of cannabinoid therapies into standard psychiatric care.
A comprehensive study published in The Lancet concludes that medicinal cannabis is largely ineffective for treating anxiety, depression, and PTSD. These findings challenge the rapidly growing global market for cannabinoid-based mental health treatments and highlight a significant gap between patient perception and clinical evidence.
This page surfaces every story mentioning Therapeutic Goods Administration (TGA) across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Therapeutic Goods Administration (TGA) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |